All relevant data are within the paper and its Supporting Information files.

Introduction {#sec006}
============

Orofacial clefts (OFC) are among the most common congenital defects with a relatively high birth prevalence of 1.66/1000 newborns in China \[[@pone.0159940.ref001]\]. Categorization according to anatomical site shows that OFCs are commonly subtyped as cleft lip only (CLO), cleft lip with palate (CLP), or cleft palate only (CPO). Given their shared epidemiological traits and embryologic origin, CLO and CLP are traditionally combined as a single subgroup, namely, cleft lip with or without cleft palate (CL/P) \[[@pone.0159940.ref002]\]. Nevertheless, an increasing number of evidence indicates CLO and CLP might have different genetic origins and would be better analyzed as distinct entities \[[@pone.0159940.ref003]\]. Most OFCs occur as non-syndromic (NS) cases where clefting occurs as the only malformation in the affected infant, and are thought to be caused by the interplay between environmental and genetic factors \[[@pone.0159940.ref004]\]. Although previous studies of linkage and candidate genes, and more recently, several genome-wide association studies (GWAS), have reported multiple risk loci associated with NSOFC \[[@pone.0159940.ref005]--[@pone.0159940.ref010]\], the underlying genetic architecture of this birth defect remains largely unknown.

A powerful molecular approach with which to study the genetics of NSOFC is to investigate causative genes for syndromic clefting. Interferon regulatory factor 6 (*IRF6*) is one such candidate gene, and mutations in *IRF6* cause Van der Woude syndrome (VWS, \[MIM 119300\]), the most common type of syndromic OFC, or popliteal pterygium syndrome (PPS, \[MIM 119500\]) \[[@pone.0159940.ref011]\]. Furthermore, variants in *IRF6* show a strong association with NSOFC, especially with the CLO subtype \[[@pone.0159940.ref012]\]. However, findings from different studies have been inconsistent and the risk association of NSOFC with particular variants of *IRF6* may differ depending on ethnic background \[[@pone.0159940.ref013]--[@pone.0159940.ref015]\]. Thus far, mutations in *IRF6* have been identified in only 70% of families with VWS. A linkage study for a large Finnish pedigree with VWS identified a novel locus on 1p33--p36 (VWS2) rather than *IRF6* at 1q32--q41, providing further evidence of locus heterogeneity underlying this syndrome \[[@pone.0159940.ref016]\]. Further mutation screening in VWS families without *IRF6* mutation demonstrated that *GRHL3* is the second reported gene for which mutations resulting in VWS. Phenotypic analyses of murine embryos with double heterozygous knockout (*Irf6*^+/-^; *Grhl3*^+/-^) indicated that both genes play pivotal roles in the development of the functional periderm, and disturbing this process leads to VWS \[[@pone.0159940.ref017]\]. Functional analyses also showed *Grhl3* is a key downstream target of *Irf6* in the process of periderm differentiation \[[@pone.0159940.ref018]\]. Taken together, previous studies demonstrate mutations in both *IRF6* and *GRHL3* cause almost the same clefting phenotypes. Furthermore, the recent studies by GWAS and sequencing approaches have indicated a missense variant (rs41268753) in *GRHL3* increases risk for NSCPO cases of European ancestry \[[@pone.0159940.ref010], [@pone.0159940.ref019]\]. However, the allele frequency for rs41268753 minor alleles is zero in Chinese population according to the same report and the Hapmap database. More recently, an association study genotyped multiple tag single nucleotide polymorphisms (SNPs) spanning the *GRHL3* gene in Chinese NSCL/P patients and controls and had not reached a clear-out conclusion that any genotype or haplotype variant is associated with the susceptibility to NSCL/P in this cohort \[[@pone.0159940.ref020]\]. Hence, we examined other common functional variants in *GRHL3* (rather than rs41268753 itself) involved in the pathogenesis of NSOFC in a Chinese Han population. The aim of this study was to investigate any possible association between *GRHL3* polymorphisms and susceptibility to NSOFC in this Han Chinese population.

Materials and Methods {#sec007}
=====================

Study population and DNA samples {#sec008}
--------------------------------

The Ethics Committee of School of Stomatology, Wuhan University, Wuhan, China (protocol number: 2014--20) has approved this study. All applicable regulations concerning the use of human DNA were followed. A cohort comprising 768 cases, and 377 controls, was used for genotyping and all subjects were ethnic Han Chinese. Any associated anomalies or syndromes were excluded by two experienced surgeons and only those diagnosed with NSOFC were thus included. All participants or their guardians have signed the informed consent forms. Peripheral venous blood samples were collected and genomic DNA was extracted as previously described \[[@pone.0159940.ref009]\].

Selection of *GRHL3* polymorphisms {#sec009}
----------------------------------

Functional SNPs for *GRHL3* located in either the coding region or the regulatory elements (5'-flanking region and 5'/3'-untranslated regions) with the minor allele frequency (MAF) \> 5% in Han Chinese population were selected from the International HapMap Project database ([http://hapmap.ncbi.nlm.nih.gov](http://hapmap.ncbi.nlm.nih.gov/)), and the National Center for Biotechnology Information (NCBI) database (<http://www.ncbi.nlm.nih.gov/projects/SNP>).

Genotyping {#sec010}
----------

The TaqMan 5′-exonuclease allelic discrimination assay (Applied Biosystems, Foster City, CA) was used to perform the genotyping. Technicians were blinded to the case or control status of individuals when performing it. Finally, genotyping was randomly replicated for 10% of samples to ensure genotypic consistency.

Statistical analyses {#sec011}
--------------------

The Hardy-Weinberg equilibrium (HWE) was evaluated for both polymorphisms in the control group. Statistical analyses of case *vs*. control status was performed using the SPSS package to test the null hypothesis of independence between disease and marker genotypes (SPSS Inc., Chicago, IL, USA). Comparison of genotype and allele frequencies among cases, and the control group, were performed by the Chi-square test. Odds ratios (ORs) with 95% confidence intervals (CI) were computed from unconditional logistic regression analyses. Pairwise linkage disequilibrium (LD) was indicated as both Lewontin D′ and r^2^ values by use of the Haploview program (<http://www.broad.mit.edu/mpg/haploview/index.php/>).

Results {#sec012}
=======

Characteristics of the genotyped cohort {#sec013}
---------------------------------------

The case and control groups were satisfactorily matched for gender (P \> 0.05). According to clinical manifestations, 768 NSOFC patients were divided into four main subgroups: 297 CPO patients and 471 CL/P patients, which were further subdivided into 214 CLO patients and 257 CLP patients, respectively.

SNP data {#sec014}
--------

Both selected tag SNPs (rs2486668 and rs545809) in *GRHL3* are described in [Table 1](#pone.0159940.t001){ref-type="table"}. These were successfully genotyped, with a call rate \> 99% ([S1](#pone.0159940.s001){ref-type="supplementary-material"} and [S2](#pone.0159940.s002){ref-type="supplementary-material"} Figs, [S1 Table](#pone.0159940.s003){ref-type="supplementary-material"}). Again, 10% of samples were randomly selected for duplicate genotyping, which resulted in completely concordant results. The genotypic frequencies of each SNP conformed to the Hardy--Weinberg equilibrium (both P \> 0.05) among controls, indicating there is no population stratification present in this study.

10.1371/journal.pone.0159940.t001

###### General information for genotyped SNPs.

![](pone.0159940.t001){#pone.0159940.t001g}

  SNP ID      Gene      Chr.   Posotion   Region    SNPs   Function   Amino Acid Changes                                                                     MAF[^a^](#t001fn001){ref-type="table-fn"} (CHB)   HWE[^b^](#t001fn002){ref-type="table-fn"} (P-value)
  ----------- --------- ------ ---------- --------- ------ ---------- -------------------------------------------------------------------------------------- ------------------------------------------------- -----------------------------------------------------
  rs2486668   *GRHL3*   1      24658063   exon 2    C\>G   missense   Asp[^c^](#t001fn003){ref-type="table-fn"}→Glu[^d^](#t001fn004){ref-type="table-fn"}    0.22                                              0.996
  rs545809    *GRHL3*   1      24690764   exon 16   T\>A   missense   Met[^e^](#t001fn005){ref-type="table-fn"}→ Lys[^f^](#t001fn006){ref-type="table-fn"}   0.42                                              0.997

^a^MAF, minor allele frequency; CHB, Chinese Han ~~Chinese~~ in Beijing, China.

^b^Hardy-Weinberg equilibrium among controls.

^c^Asp, aspartic acid.

^d^Glu, glutamic acid.

^e^ Met, methionine.

^f^ Lys, lysine.

Distribution of genotypic and allele frequencies {#sec015}
------------------------------------------------

The MAFs of the tested SNPs in the controls were similar to those recorded in the HapMap CHB cohort. As listed in [Table 2](#pone.0159940.t002){ref-type="table"}, the frequencies of the rs2486668 CC, CG, and GG genotypes (62.5%, 33.2% and 4.3%, respectively) in both controls and NSOFC cases were identical (P = 0.994). Significant differences were not observed in allele frequencies between groups. Further logistic regression analyses unraveled that neither the CG heterozygote, nor the GG homozygote, conferred to NSOFC risk when comparing with the wild-type homozygote (OR = 1.00, 95% CI = 0.77--1.30 for CG and OR = 1.01, 95% CI = 0.54--1.87 for GG, respectively). Analyses using different genetic models also uncovered no differences in genotype distribution between NSOFC cases and controls. Given that genetic etiologies may be diverse in different subtypes of NSOFC, a stratified analysis was also conducted for CL/P, CLP, CLO, and CPO, respectively. We observed that for rs2486668, overall genotype and allele frequencies for the subgroups differed slightly from those in controls. However, the differences were not statistically significant between controls and each subgroup, and a lack of any significant association was also observed in logistic regression analyses under these different models of inheritance.

10.1371/journal.pone.0159940.t002

###### Genotypic and allelic distributions of rs2486668 in NSOFC cases and controls.

![](pone.0159940.t002){#pone.0159940.t002g}

  rs2486668                                 Controls (n = 376,%)   All cleft cases (n = 768,%)   CL/P (n = 471, %)   CLP (n = 257, %)   CLO (n = 214, %)   CPO (n = 297, %)
  ----------------------------------------- ---------------------- ----------------------------- ------------------- ------------------ ------------------ ------------------
  **Genotype**                                                                                                                                             
  CC                                        235(62.5)              480(62.5)                     290(61.6)           161(62.6)          129(60.3)          190(64.0)
  CG                                        125(33.2)              255(33.2)                     157(33.3)           85(33.1)           72(33.6)           98(33.0)
  GG                                        16(4.3)                33(4.3)                       24(5.1)             11(4.3)            13(6.1)            9(3.0)
  P^a^                                      \-                     0.994                         0.8428              0.999              0.5963             0.694
  **OR(95% CI)**                                                                                                                                           
  CG vs. CC                                 \-                     1.00(0.77, 1.30)              1.02(0.80, 1.30)    0.99(0.72, 1.38)   1.05(0.71, 1.55)   0.97(0.66, 1.41)
  GG vs. CC                                 \-                     1.01(0.54, 1.87)              1.22(0.70,1.80)     1.00(0.48, 2.10)   1.48(0.64, 3.41)   0.70(0.29, 1.68)
  CG/GG vs. CC                              \-                     1.00(0.78, 1.29)              1.04(0.82,1.32)     0.99(0.73, 1.36)   1.09(0.76, 1.60)   0.93(0.65, 1.35)
  CG/CC vs. GG                              \-                     0.99(0.54, 1.82)              0.83(0.48, 1.41)    0.99(0.48, 2.06)   0.69(0.30, 1.57)   1.42(0.60, 3.39)
  **Alleles**                                                                                                                                              
  C                                         0.79                   0.79                          0.78                0.79               0.77               0.8
  G                                         0.21                   0.21                          0.22                0.21               0.23               0.2
  P[^a^](#t002fn002){ref-type="table-fn"}   \-                     1                             0.8592              0.9538             0.8989             0.8431

CL/P, cleft lip with or without cleft palate; CLP, cleft lip with palate; CLO, cleft lip only; CPO, cleft palate only; OR, odds ratio; CI, confidence interval.

^a^Comparison of genotype and allele frequencies among cases and controls were performed by two-sided Chi-square test.

Similar data were also observed for rs545809 ([Table 3](#pone.0159940.t003){ref-type="table"}). We could not identify any relationship between rs545809 and the risk of NSOFC using general or stratified analyses. In the LD analyses, we found no strong linkage disequilibrium (D' = 0.177; r^2^ = 0.571) between the two SNPs (rs2486668 and rs545809). Given the lack of association with single marker analyses, haplotypes of these two markers would not differ between cases and controls. Therefore, haplotype analyses were not undertaken here.

10.1371/journal.pone.0159940.t003

###### Genotypic and allelic distributions of rs545809 in NSOFC cases and controls.

![](pone.0159940.t003){#pone.0159940.t003g}

  rs545809                                  Controls (n = 376,%)   All cleft cases (n = 768,%)   CL/P (n = 471, %)   CLP (n = 257, %)   CLO (n = 214, %)   CPO (n = 297, %)
  ----------------------------------------- ---------------------- ----------------------------- ------------------- ------------------ ------------------ ------------------
  **Genotype**                                                                                                                                             
  TT                                        139(37.0)              284(37.0)                     157(33.3)           94(36.6)           63(29.4)           127(42.8)
  AT                                        180(47.9)              368(47.9)                     235(50.0)           117(45.5)          118(55.1)          133(44.8)
  AA                                        57(15.2)               116(15.1)                     79(16.8)            46(17.9)           33(15.4)           37(12.5)
  P[^a^](#t003fn002){ref-type="table-fn"}   \-                     0.9997                        0.7195              0.7782             0.4741             0.1575
  **OR(95%CI)**                                                                                                                                            
  AT vs. TT                                 \-                     1.00(0.76, 1.31)              1.16(0.90, 1.49)    0.96(0.69, 1.35)   1.45(0.96, 2.18)   0.81(0.55, 1.20)
  AA vs. TT                                 \-                     1.00(0.68, 1.45)              1.23(0.87, 1.73)    1.19(0.77, 1.86)   1.28(0.74, 2.21)   0.71(0.41, 1.24)
  AT/AA vs. TT                              \-                     1.00(0.77, 1.29)              1.17(0.92, 1.49)    1.02(0.74, 1.40)   1.41(0.95, 2.07)   0.79(0.54, 1.14)
  AT/TT vs. AA                              \-                     1.00(0.71, 1.42)              0.89(0.65, 1.21)    0.82(0.55, 1.22)   0.98(0.60, 1.60)   1.26(0.76, 2.08)
  **Alleles**                                                                                                                                              
  T                                         0.61                   0.61                          0.58                0.59               0.57               0.65
  A                                         0.39                   0.39                          0.42                0.41               0.43               0.35
  P[^a^](#t003fn002){ref-type="table-fn"}   \-                     1                             0.3772              0.5578             0.4725             0.0769

CL/P, cleft lip with or without cleft palate; CLP, cleft lip with palate; CLO, cleft lip only; CPO, cleft palate only; OR, odds ratio; CI, confidence interval.

^a^Comparison of genotype and allele frequencies among cases and controls were performed by two-sided Chi-square test.

Discussion {#sec016}
==========

NSOFC is a complex malformation, thought to be of multifactorial etiology, with both genetic and environmental elements. This complexity has impeded the process of screening causal genetic risk factors \[[@pone.0159940.ref004]\]. In the past few decades, candidate gene-based approaches have proven to be a useful tool with which to investigate the genetic components of NSOFC. However, thus far, only *IRF6* has shown any convincing degree of consistency across studies \[[@pone.0159940.ref003], [@pone.0159940.ref012],[@pone.0159940.ref013]\]. *GRHL3* was recently identified as a second causative gene for VWS, providing a prominent candidate susceptible gene for NSOFC \[[@pone.0159940.ref017]\]. Furthermore, a missense variant in *GRHL3* was identified to be associated with the risk for NSCPO in European population \[[@pone.0159940.ref010], [@pone.0159940.ref019]\]. A recent association study was performed in Chinese NSCL/P patients using ten tag SNPs of *GRHL3* and did not give an affirmative answer that this gene contributes to NSCL/P etiology in the Chinese Han population \[[@pone.0159940.ref020]\]. Therefore, it is necessary to further investigate whether there are other common functional variants in *GRHL3* involved in the pathogenesis of NSOFC, especially NSCPO, in the Chinese population.

Grainyhead genes encode a well conserved family of transcription factors including three members, Grhl1, 2, and 3 in mice, which have ubiquitous expression patterns in the process of embryonic development, and in adult skin cells. Despite sharing extensive sequence homology, overlapping expression patterns, and a consensus in DNA binding sequence, *Grhl3* is indispensable in the courses of neural tube closure, skin barrier formation and wound healing \[[@pone.0159940.ref021]\]. *Grhl3* is directly regulated by *Irf6*, but functions in independent, but convergent pathways during palatogenesis \[[@pone.0159940.ref017], [@pone.0159940.ref018]\]. In *Irf6* deficient mice, orofacial clefting was caused by abnormal periderm differentiation and a failed disappearance of the medial edge epithelium (MEE). Conversely, the MEE was successfully cleared in *Grhl3*^*-/-*^ embryos. Thus the common feature of *Irf6* and *Grhl3* mutants may be a failed periderm development, providing further confirmation of a role for the oral periderm in orofacial development. Mutations in the *IRF6* and *GRHL3* genes can lead to VWS, with a dysfunctional oral periderm contributing to the phenotypes of orofacial clefts in humans \[[@pone.0159940.ref017]\].

Although locus heterogeneity for VWS was further confirmed, we also noted that the deleterious mutations in *GRHL3* may not be prevalent in VWS pedigrees without mutations in *IRF6* \[[@pone.0159940.ref017]\]. Sequencing of the coding regions of the *GRHL3* gene in three Chinese VWS-affected families lacking *IRF6* mutations identified no new pathogenic mutations (unpublished data). In the mouse, *Grhl3*^*-/-*^ embryos with an abnormal oral periderm developed cleft palate at low penetrance (17%) \[[@pone.0159940.ref017]\]. Potential causative genes for VWS awaits being identified in the future. So far, the precise biological role of *Grhl3* in facial morphogenesis is still elusive. In vivo functional dissection of *GRHL3* missense variants will be performed in zebrafish models in our future study. In addition, identification of the downstream targets of the Irf6-Grhl3 network will help not only to enrich our knowledge of craniofacial development, but also to provide more candidates involved in the genetic etiology of syndromic and/or non-syndromic clefting in humans.

The results presented in the current study are frustrating, although not entirely unexpected given the heterogeneous nature of NSOFC. First, population differences may affect the results of genetic association study in complex diseases. For example, inconsistent results in *IRF6* association studies have been reported using patient cohorts derived from distinct regions within China \[[@pone.0159940.ref013]--[@pone.0159940.ref015]\]. The common variant (rs41268753) in the *GRHL3* locus identified by the recent GWAS and sequencing is associated with the risk to NSCPO in European population, but not in several Asian and African-derived populations \[[@pone.0159940.ref010], [@pone.0159940.ref019]\]. Further well-designed studies including diverse ethnic backgrounds are now warranted. Second, we adopted stratified analyses in this study in which CL/P and CPO were analyzed separately as distinct entities.The VWS-affected patients with *GRHL3* mutations were reported to have a higher proportion of having CP than those with *IRF6* mutations \[[@pone.0159940.ref017]\]. The results from GWAS and sequencing have also found the SNP (rs41268753) in *GRHL3* is associated with NSCPO, but not with NSCL/P \[[@pone.0159940.ref010], [@pone.0159940.ref019]\]. The association analysis in the Chinese CL/P patients identified two SNPs and a haplotype of *GRHL3* that reached the significance level, but none of them survived the multiple comparisons \[[@pone.0159940.ref020]\]. Third, the limited sample size may also have affected the results of our study. However, the number of NSCPO cases in the current study is comparable to the recent GWAS that found the *GRHL3* hit \[[@pone.0159940.ref010]\]. Meanwhile, the MAFs of both SNPs for controls from this study and from publicly-available databases are very similar, indicating favorable quality control. Therefore, increasing the sample size is unlikely to have any effect. Lastly, considering more markers as haplotypes be a more efficient analytic tool in this situation than the study of one or two SNPs at the population level \[[@pone.0159940.ref022]\]. However, the original purpose of this study was to investigate the potential link between common functional variants in *GRHL3* and risk to NSOFC in the Han Chinese population. Only two SNPs met the selection criteria and were used in this study. Given the lack of association with single marker analyses, it is now imperative to conduct additional SNP-based haplotype analyses and re-sequencing studies in the future.

In summary, this preliminary study investigated whether *GRHL3* was involved in the pathogenesis of non-syndromic clefting in the Han Chinese population. Our findings failed to detect two missense variants (rs2486668 and rs545809) in *GRHL3* contribute to NSOFC risk in Han Chinese cases and controls. More cohort-based studies with wider SNP coverage of the *GRHL3* locus, recruiting from different ethnic populations, are still warranted to further verify any relationship between *GRHL3* and risk to NSOFC.
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